Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Immune checkpoint blockades, such as inhibitors against programmed death 1 (PD-1) and its ligand (PD-L1), have received extensive attention in the past decade because of their dramatic clinical outcomes in advanced malignancies. However, both primary and acquired resistance becomes one of the major...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Jie, Gao, Zhitao, Li, Xiang, Dong, Liang, Han, Weidong, Nie, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746415/
https://www.ncbi.nlm.nih.gov/pubmed/29299180
http://dx.doi.org/10.18632/oncotarget.22690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746415/
https://www.ncbi.nlm.nih.gov/pubmed/29299180
http://dx.doi.org/10.18632/oncotarget.22690

Ejemplares similares